Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities
Elizabeth Anne Maher, Cameron Walter Brennan, Patrick Yung Wen et al. · Cancer Research · 2006
Glioblastoma is classified into two subtypes on the basis of clinical history: "primary glioblastoma" arising de novo without detectable antecedent disease and "secondary glioblastoma" evolving from a low-grade astrocytoma. Despite their distinctive clinical courses, they arrive at an indistinguishable clinical and pathologic end point highlighted by widespread invasion and resistance to therapy and, as such, are managed clinically as if they are one disease entity. Because the life history of a cancer cell is often reflected in the pattern of genomic alterations, we sought to determine whether primary and secondary glioblastomas evolve through similar or different molecular pathogenetic routes. Clinically annotated primary and secondary glioblastoma samples were subjected to high-resolution copy number analysis using oligonucleotide-based array comparative genomic hybridization. Unsupervised classification using genomic nonnegative matrix factorization methods identified three distinct genomic subclasses. Whereas one corresponded to clinically defined primary glioblastomas, the remaining two stratified secondary glioblastoma into two genetically distinct cohorts. Thus, this global genomic analysis showed wide-scale differences between primary and secondary glioblastomas that were previously unappreciated, and has shown for the first time that secondary glioblastoma is heterogeneous in its molecular pathogenesis. Consistent with these findings, analysis of regional recurrent copy number alterations revealed many more events unique to these subclasses than shared. The pathobiological significance of these shared and subtype-specific copy number alterations is reinforced by their frequent occurrence, resident genes with clear links to cancer, recurrence in diverse cancer types, and apparent association with clinical outcome. We conclude that glioblastoma is composed of at least three distinct molecular subtypes, including novel subgroups of secondary glioblastoma, which may benefit from different therapeutic strategies.
Cited by 210 works. doi:10.1158/0008-5472.can-06-2072 Open-access PDF
Authors
- Elizabeth Anne Maher
- Cameron Walter Brennan
- Patrick Yung Wen
- Laura E. Durso
- Keith Lloyd Ligon
- Aaron D. Richardson
- Deepak Khatry
- Raktim Sinha
- David N. Louis
- John Quackenbush
- Peter McL. Black
- Lynda Chin
- Ronald Anthony DePinho
References
- Circular binary segmentation for the analysis of array-based DNA copy number data
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
- Metagenes and molecular pattern discovery using matrix factorization
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
- Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
- Phase II Trial of Gefitinib in Recurrent Glioblastoma
- Extensive modulation of a set of microRNAs in primary glioblastoma
- Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas
- Malignant glioma: genetics and biology of a grave matter
- Primary and secondary glioblastomas: From concept to clinical diagnosis